396 related articles for article (PubMed ID: 35465692)
1. Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.
Valero A; Ibáñez-Echevarría E; Vidal C; Raducan I; Castelló Carrascosa JV; Sánchez-López J
Immunotherapy; 2022 Jun; 14(9):683-694. PubMed ID: 35465692
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
Huang HH; Xu C; Liu L; Chai RN
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
[No Abstract] [Full Text] [Related]
3. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
4. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
[TBL] [Abstract][Full Text] [Related]
5. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
[TBL] [Abstract][Full Text] [Related]
7. Dust mite component Analysis: Identifying key allergens components for effective immunotherapy in allergic rhinitis.
Huang J; Xiang R; Tan L; Deng Y; Tao Z; Zhang W; Xu Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111111. PubMed ID: 37925948
[TBL] [Abstract][Full Text] [Related]
8. Comparison of rush-subcutaneous and sublingual immunotherapy with house dust mite extract for pediatric allergic rhinitis: A prospective cohort study.
Hamada M; Saeki K; Tanaka I
Allergol Int; 2023 Oct; 72(4):573-579. PubMed ID: 36918306
[TBL] [Abstract][Full Text] [Related]
9. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
13. The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study.
Tu Y; Zhang H; Zhao L; Jin P; Zi X; Li T; Shi L; Zhi L
J Laryngol Otol; 2019 Mar; 133(3):213-219. PubMed ID: 30674357
[TBL] [Abstract][Full Text] [Related]
14. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial.
Demoly P; Corren J; Creticos P; De Blay F; Gevaert P; Hellings P; Kowal K; Le Gall M; Nenasheva N; Passalacqua G; Pfaar O; Tortajada-Girbés M; Vidal C; Worm M; Casale TB
J Allergy Clin Immunol; 2021 Mar; 147(3):1020-1030.e10. PubMed ID: 32890575
[TBL] [Abstract][Full Text] [Related]
15. Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period.
Soh JY; Thalayasingam M; Ong S; Loo EX; Shek LP; Chao SS
J Laryngol Otol; 2016 Mar; 130(3):272-7. PubMed ID: 26781592
[TBL] [Abstract][Full Text] [Related]
16. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.
Wang ZX; Shi H
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Subcutaneous and Sublingual Immunotherapy for House Dust Mite Allergy: A Network Meta-Analysis-Based Comparison.
Kim JY; Jang MJ; Kim DY; Park SW; Han DH
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4450-4458.e6. PubMed ID: 34464748
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial.
Varney VA; Tabbah K; Mavroleon G; Frew AJ
Clin Exp Allergy; 2003 Aug; 33(8):1076-82. PubMed ID: 12911781
[TBL] [Abstract][Full Text] [Related]
19. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
Richards JR; Stumpf JL
Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
[TBL] [Abstract][Full Text] [Related]
20. Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy.
Liu Y; Xing Z; Wang J; Geng C
Am J Rhinol Allergy; 2018 Nov; 32(6):458-464. PubMed ID: 30124065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
